Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | LOX | P28300 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272540 | 0.89 | HTR6 (0.39) | HTR6HSD11B1ALDH1A1TSHR | |
| (Phenylsulfonyl)Benzene SCHEMBL29090883 | 0.79 | HTR6 (0.70) | HTR6LOXNPSR1MAOALOXL2 | |
| SCHEMBL11401258 | 0.79 | HSD11B1 (0.44) | HTR6HSD11B1NPSR1CYP2E1CYP2A6 | |
| SCHEMBL15285333 | 0.79 | GAA (0.64) | ALDH1A1SMN1; SMN2TDP1CA12CA1 | |
| (Phenylsulfonyl)Benzene SCHEMBL29473549 | 0.78 | HTR6 (1.00) | HTR6ALDH1A1SMN1; SMN2TSHRHSD17B10 | |
| (Phenylsulfonyl)Benzene SCHEMBL29450723 | 0.78 | HTR6 (1.00) | HTR6ALDH1A1SMN1; SMN2TSHRHSD17B10 | |
| (Phenylsulfonyl)Benzene SCHEMBL29775288 | 0.78 | HTR6 (1.00) | HTR6ALDH1A1SMN1; SMN2TSHRHSD17B10 | |
| (Phenylsulfonyl)Benzene SCHEMBL13735236 | 0.78 | HTR6 (1.00) | HTR6ALDH1A1SMN1; SMN2TSHRHSD17B10 | |
| (Phenylsulfonyl)Benzene SCHEMBL30255 | 0.78 | HTR6 (1.00) | HTR6ALDH1A1SMN1; SMN2TSHRHSD17B10 | |
| (Phenylsulfonyl)Benzene SCHEMBL28119187 | 0.78 | HTR6 (1.00) | HTR6ALDH1A1SMN1; SMN2TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024098538-A1 | METHOD FOR MANUFACTURING SOLAR CELL BY DOPING PEROVSKITE BULK WITH SULFONYL MOLECULES | 中国科学院合肥物质科学研究院 | 2024-05-16 | — | — | WO | claimed |
| CN-115633531-A | Method for preparing solar cell by doping sulfonyl molecules in perovskite phase | 中国科学院合肥物质科学研究院 | 2023-01-20 | — | — | CN | claimed |
| WO-2024098538-A1 | METHOD FOR MANUFACTURING SOLAR CELL BY DOPING PEROVSKITE BULK WITH SULFONYL MOLECULES | 中国科学院合肥物质科学研究院 | 2024-05-16 | — | — | WO | disclosed |
| CN-115633531-A | Method for preparing solar cell by doping sulfonyl molecules in perovskite phase | 中国科学院合肥物质科学研究院 | 2023-01-20 | — | — | CN | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-8008425-B2 | Thiophene compound having sulfonyl group and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008425-B2 | Thiophene compound having sulfonyl group and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20090127491-A1 | THIOPHENE COMPOUND HAVING SULFONYL GROUP AND PROCESS FOR PRODUCING THE SAME | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090127491-A1 | THIOPHENE COMPOUND HAVING SULFONYL GROUP AND PROCESS FOR PRODUCING THE SAME | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1083980-B1 | MODULATION OF MOLECULAR INTERACTION SITES ON RNA AND OTHER BIOMOLECULES | ISIS PHARMACEUTICALS INC (US) | 2007-03-21 | — | — | EP | disclosed |
| US-6969763-B1 | Molecular interaction sites of interleukin-2 RNA and methods of modulating the same | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-29 | — | — | US | disclosed |
| WO-2003091268-A1 | MOLECULAR INTERACTION SITES OF VIMENTIN RNA AND METHODS OF MODULATING THE SAME | ISIS PHARMACEUTICALS, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-6492403-B1 | TREATING SYMPTOMS OF ACUTE OR CHRONIC DISORDER MEDIATED BY CLASSICAL PATHWAY OF COMPLEMENT CASCADE; PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1083980-A2 | MODULATION OF MOLECULAR INTERACTION SITES ON RNA AND OTHER BIOMOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-1077993-A1 | GENERATION OF COMBINATORIAL LIBRARIES OF COMPOUNDS CORRESPONDING TO VIRTUAL LIBRARIES OF COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058947-A9 | MODULATION OF MOLECULAR INTERACTION SITES ON RNA AND OTHER BIOMOLECULES | ISIS PHARMACEUTICALS INC (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999058474-A9 | GENERATION OF COMBINATORIAL LIBRARIES OF COMPOUNDS CORRESPONDING TO VIRTUAL LIBRARIES OF COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2000-02-03 | — | — | WO | disclosed |
| WO-1999058947-A2 | MODULATION OF MOLECULAR INTERACTION SITES ON RNA AND OTHER BIOMOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999058474-A1 | GENERATION OF COMBINATORIAL LIBRARIES OF COMPOUNDS CORRESPONDING TO VIRTUAL LIBRARIES OF COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-18 | — | — | WO | disclosed |
| EP-0203438-A1 | Solution processible forms of neutral and electrically conductive poly(substituted heterocycles) | ALLIED CORPORATION (US) | 1986-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090127491-A1 | THIOPHENE COMPOUND HAVING SULFONYL GROUP AND PROCESS FOR PRODUCING THE SAME | TST, ABCG2, CBR3 | HTR6 590/4885HSD11B1 965/4885LOX 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.